Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ivan Jambor, Ph.D., M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Falagario UG, Chakravarty D, Martini A, Shahait M, El-Fahmawi A, Jambor I, Lantz A, Grannas D, Ratnani P, Parekh S, Lundon D, Haines K, Cormio L, Carrieri G, Kyprianou N, Kattan MW, Klein EA, Wiklund P, Lee DI, Tewari A. When to order genomic tests: development and external validation of a model to predict high-risk prostate cancer at the genotypic level. World J Urol. 2023 Jan; 41(1):85-92. PMID: 36484816.
    Citations:    Fields:    Translation:Humans
  2. Peters M, Eldred-Evans D, Kurver P, Falagario UG, Connor MJ, Shah TT, Verhoeff JJC, Taimen P, Aronen HJ, Knaapila J, Montoya Perez I, Ettala O, Stabile A, Gandaglia G, Fossati N, Martini A, Cucchiara V, Briganti A, Lantz A, Picker W, Haug ES, Nordström T, Tanaka MB, Reddy D, Bass E, van Rossum PSN, Wong K, Tam H, Winkler M, Gordon S, Qazi H, Boström PJ, Jambor I, Ahmed HU. Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert =3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score. Eur Urol. 2022 11; 82(5):559-568. PMID: 35963650.
    Citations: 2     Fields:    Translation:Humans
  3. Beheshti M, Taimen P, Kemppainen J, Jambor I, Müller A, Loidl W, Kähkönen E, Käkelä M, Berndt M, Stephens AW, Minn H, Langsteger W. Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study. Eur Radiol. 2023 Jan; 33(1):472-482. PMID: 35864350; PMCID: PMC9755087.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  4. Chakravarty D, Ratnani P, Huang L, Dovey Z, Sobotka S, Berryhill R, Merisaari H, Al Shaarani M, Rai R, Jambor I, Yadav KK, Mittan S, Parekh S, Kodysh J, Wagaskar V, Brody R, Cordon-Cardo C, Rykunov D, Reva B, Davicioni E, Wiklund P, Bhardwaj N, Nair SS, Tewari AK. Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer. Cancers (Basel). 2022 May 31; 14(11). PMID: 35681714; PMCID: PMC9179284.
  5. Parekh S, Ratnani P, Falagario U, Lundon D, Kewlani D, Nasri J, Dovey Z, Stroumbakis D, Ranti D, Grauer R, Sobotka S, Pedraza A, Wagaskar V, Mistry L, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, Aronen HJ, Knaapila J, Perez IM, Gandaglia G, Martini A, Picker W, Haug E, Cormio L, Nordström T, Briganti A, Boström PJ, Carrieri G, Haines K, Gorin MA, Wiklund P, Menon M, Tewari A. The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator. Eur Urol Open Sci. 2022 Jul; 41:45-54. PMID: 35813258; PMCID: PMC9257660.
    Citations: 1     
  6. Arvola S, Seppänen M, Malaspina S, Mätzke S, Raiko J, Timonen KL, Ettala O, Jambor I, Anttinen M, Kuisma A, Löyttyniemi E, Boström PJ, Sohlberg A, Noponen T. Comparison of reprojected bone SPECT/CT and planar bone scintigraphy for the detection of bone metastases in breast and prostate cancer. Nucl Med Commun. 2022 May 01; 43(5):510-517. PMID: 35081092.
    Citations: 1     Fields:    Translation:Humans
  7. Ratnani P, Dovey Z, Parekh S, Sobotka S, Shukla D, Davis A, Roshandel R, Wagaskar V, Jambor I, Lundon DJ, Wiklund P, Kyprianou N, Menon M, Tewari A. Prostate MRI percentage tumor involvement or "PI-RADS percent" as a predictor of adverse surgical pathology. Prostate. 2022 06; 82(9):970-983. PMID: 35437769.
    Citations:    Fields:    Translation:Humans
  8. Ettala O, Jambor I, Montoya Perez I, Seppänen M, Kaipia A, Seikkula H, Syvänen KT, Taimen P, Verho J, Steiner A, Saunavaara J, Saukko E, Löyttyniemi E, Sjoberg DD, Vickers A, Aronen H, Boström P. Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0). BMJ Open. 2022 04 15; 12(4):e053118. PMID: 35428621; PMCID: PMC9014036.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  9. Martini A, Falagario UG, Cumarasamy S, Jambor I, Wagaskar VG, Ratnani P, Haines Iii KG, Tewari AK. The Role of 3D Models Obtained from Multiparametric Prostate MRI in Performing Robotic Prostatectomy. J Endourol. 2022 03; 36(3):387-393. PMID: 34555942.
    Citations: 2     Fields:    Translation:Humans
  10. Beksac AT, Ratnani P, Dovey Z, Parekh S, Falagario U, Roshandel R, Sobotka S, Kewlani D, Davis A, Weil R, Bashorun H, Jambor I, Lewis S, Haines K, Tewari AK. Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer. Cancer Rep (Hoboken). 2022 03; 5(3):e1492. PMID: 34931468; PMCID: PMC8955055.
    Citations: 1     Fields:    Translation:Humans
  11. Jambor I, Martini A, Falagario UG, Ettala O, Taimen P, Knaapila J, Syvänen KT, Steiner A, Verho J, Perez IM, Merisaari H, Vainio P, Lamminen T, Saunavaara J, Carrieri G, Boström PJ, Aronen HJ. How to read biparametric MRI in men with a clinical suspicious of prostate cancer: Pictorial review for beginners with public access to imaging, clinical and histopathological database. Acta Radiol Open. 2021 Nov; 10(11):20584601211060707. PMID: 34868663; PMCID: PMC8638086.
  12. Tomer N, Chakravarty D, Ratnani P, Mohamed NE, Jambor I, Dovey Z, Palese MA, Tewari AK. Impact of diverticular disease on prostate cancer risk among hypertensive men. Prostate Cancer Prostatic Dis. 2022 04; 25(4):700-706. PMID: 34621012.
    Citations: 1     Fields:    Translation:Humans
  13. Nikulainen I, Salminen AP, Jambor I, Merisaari H, Tammilehto V, Taimen P, Seikkula H, Boström PJ. Visual MRI T-category versus VI-RADS evaluation from multiparametric MRI in the detection of muscle-invasion in patients with suspected bladder cancer: single centre registered clinical trial (MIB-trial). Scand J Urol. 2021 Oct; 55(5):354-360. PMID: 34448679.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  14. Montoya Perez I, Merisaari H, Jambor I, Ettala O, Taimen P, Knaapila J, Kekki H, Khan FL, Syrjälä E, Steiner A, Syvänen KT, Verho J, Seppänen M, Rannikko A, Riikonen J, Mirtti T, Lamminen T, Saunavaara J, Falagario U, Martini A, Pahikkala T, Pettersson K, Boström PJ, Aronen HJ. Detection of Prostate Cancer Using Biparametric Prostate MRI, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer. J Magn Reson Imaging. 2022 02; 55(2):465-477. PMID: 34227169.
    Citations: 5     Fields:    Translation:Humans
  15. Merisaari H, Laakso H, Liljenbäck H, Virtanen H, Aronen HJ, Minn H, Poutanen M, Roivainen A, Liimatainen T, Jambor I. Statistical Evaluation of Different Mathematical Models for Diffusion Weighted Imaging of Prostate Cancer Xenografts in Mice. Front Oncol. 2021; 11:583921. PMID: 34123770; PMCID: PMC8188898.
  16. Leo P, Janowczyk A, Elliott R, Janaki N, Bera K, Shiradkar R, Farré X, Fu P, El-Fahmawi A, Shahait M, Kim J, Lee D, Yamoah K, Rebbeck TR, Khani F, Robinson BD, Eklund L, Jambor I, Merisaari H, Ettala O, Taimen P, Aronen HJ, Boström PJ, Tewari A, Magi-Galluzzi C, Klein E, Purysko A, Nc Shih N, Feldman M, Gupta S, Lal P, Madabhushi A. Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. NPJ Precis Oncol. 2021 May 03; 5(1):35. PMID: 33941830.
    Citations: 5     
  17. Malaspina S, Anttinen M, Taimen P, Jambor I, Sandell M, Rinta-Kiikka I, Kajander S, Schildt J, Saukko E, Noponen T, Saunavaara J, Dean PB, Sequeiros RB, Aronen HJ, Kemppainen J, Seppänen M, Boström PJ, Ettala O. Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2021 08; 48(9):2951-2959. PMID: 33715033; PMCID: PMC8263440.
    Citations: 7     Fields:    Translation:Humans
  18. Jambor I, Steiner A, Pesola M, Liimatainen T, Sucksdorff M, Rissanen E, Airas L, Aronen HJ, Merisaari H. Whole Brain Adiabatic T1rho and Relaxation Along a Fictitious Field Imaging in Healthy Volunteers and Patients With Multiple Sclerosis: Initial Findings. J Magn Reson Imaging. 2021 09; 54(3):866-879. PMID: 33675564.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  19. Laakso H, Ylä-Herttuala E, Sierra A, Jambor I, Poutanen M, Liljenbäck H, Virtanen H, Merisaari H, Aronen H, Minn H, Roivainen A, Liimatainen T. Docetaxel chemotherapy response in PC3 prostate cancer mouse model detected by rotating frame relaxations and water diffusion. NMR Biomed. 2021 04; 34(4):e4483. PMID: 33543563.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  20. Falagario UG, Lantz A, Jambor I, Martini A, Ratnani P, Wagaskar V, Treacy PJ, Veccia A, Bravi CA, Bashorun HO, Phillip D, Lewis S, Haines K, Cormio L, Carrieri G, Tewari A. Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion. Int J Urol. 2021 Jan; 28(1):47-52. PMID: 32985040.
    Citations: 7     Fields:    Translation:Humans
  21. Falagario UG, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, Aronen HJ, Knaapila J, Perez IM, Gandaglia G, Fossati N, Martini A, Cucchiara V, Picker W, Haug E, Ratnani P, Haines K, Lewis S, Sujit N, Selvaggio O, Sanguedolce F, Macarini L, Cormio L, Nordström T, Tewari A, Briganti A, Boström PJ, Carrieri G. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). Eur Urol Oncol. 2021 12; 4(6):971-979. PMID: 32972896.
    Citations: 25     Fields:    Translation:Humans
  22. Lantz A, Falagario UG, Ratnani P, Jambor I, Dovey Z, Martini A, Lewis S, Lundon D, Nair S, Phillip D, Haines K, Cormio L, Carrieri G, Kryprianou N, Tewari A. Expanding Active Surveillance Inclusion Criteria: A Novel Nomogram Including Preoperative Clinical Parameters and Magnetic Resonance Imaging Findings. Eur Urol Oncol. 2022 04; 5(2):187-194. PMID: 32891599.
    Citations: 5     Fields:    Translation:Humans
  23. Jambor I, Falagario UG, Martini A, Eldred-Evans D, Ahmed HU, Boström PJ. Re: Antonio C. Westphalen, Charles E. McCulloch, Jordan M. Anaokar, et al. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology 2020;296:76-84: Can the Positive Predictive Value of Prostate MRI in Correlation with Biopsy Findings be Interpreted Without Diving into Details? Eur Urol Oncol. 2020 10; 3(5):714-715. PMID: 32873531.
    Citations:    Fields:    Translation:Humans
  24. Falagario U, Jambor I, Taimen P, Syvänen KT, Kähkönen E, Merisaari H, Montoya Perez I, Knaapila J, Steiner A, Verho J, Tewari A, Aronen HJ, Carrieri G, Boström PJ, Ettala O. Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study. World J Urol. 2021 Jun; 39(6):1879-1887. PMID: 32778912; PMCID: PMC8217016.
    Citations: 8     Fields:    Translation:Humans
  25. Hiremath A, Shiradkar R, Merisaari H, Prasanna P, Ettala O, Taimen P, Aronen HJ, Boström PJ, Jambor I, Madabhushi A. Test-retest repeatability of a deep learning architecture in detecting and segmenting clinically significant prostate cancer on apparent diffusion coefficient (ADC) maps. Eur Radiol. 2021 Jan; 31(1):379-391. PMID: 32700021; PMCID: PMC7821380.
    Citations: 7     Fields:    Translation:Humans
  26. Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta-Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, Löyttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Seppänen M, Boström PJ. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). Eur Urol Oncol. 2021 08; 4(4):635-644. PMID: 32675047.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  27. Movahedi P, Merisaari H, Perez IM, Taimen P, Kemppainen J, Kuisma A, Eskola O, Teuho J, Saunavaara J, Pesola M, Kähkönen E, Ettala O, Liimatainen T, Pahikkala T, Boström P, Aronen H, Minn H, Jambor I. Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI. Sci Rep. 2020 06 10; 10(1):9407. PMID: 32523075; PMCID: PMC7287051.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  28. Knaapila J, Jambor I, Ettala O, Taimen P, Verho J, Perez IM, Kiviniemi A, Pahikkala T, Merisaari H, Lamminen T, Saunavaara J, Aronen HJ, Syvänen KT, Boström PJ. Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies. Eur Urol Focus. 2021 May; 7(3):522-531. PMID: 32418878.
    Citations: 4     Fields:    Translation:Humans
  29. Falagario UG, Jambor I, Ratnani P, Martini A, Treacy PJ, Wajswol E, Lantz A, Papastefanou G, Weil R, Phillip D, Lewis S, Haines K, Cormio L, Carrieri G, Kyprianou N, Wiklund P, Tewari AK. Performance of prostate multiparametric MRI for prediction of prostate cancer extra-prostatic extension according to NCCN risk categories: implication for surgical planning. Minerva Urol Nefrol. 2020 Dec; 72(6):746-754. PMID: 32182231.
    Citations: 7     Fields:    Translation:Humans
  30. Falagario UG, Ratnani P, Lantz A, Jambor I, Dovey Z, Verma A, Treacy PJ, Sobotka S, Martini A, Bashorun H, Ashan M, Wagaskar VG, Lewis S, Cormio L, Carrieri G, Kyprianou N, Mohamed N, Tewari A. Staging Accuracy of Multiparametric Magnetic Resonance Imaging in Caucasian and African American Men Undergoing Radical Prostatectomy. J Urol. 2020 Jul; 204(1):82-90. PMID: 31977261.
    Citations: 15     Fields:    Translation:Humans
  31. Knaapila J, Autio V, Jambor I, Ettala O, Verho J, Kiviniemi A, Taimen P, Perez IM, Aronen HJ, Syvänen KT, Boström PJ. Impact of biparametric prebiopsy prostate magnetic resonance imaging on the diagnostics of clinically significant prostate cancer in biopsy naïve men. Scand J Urol. 2020 Feb; 54(1):7-13. PMID: 31914846.
    Citations:    Fields:    Translation:Humans
  32. Jambor I, Falagario U. Does prostate magnetic resonance imaging (MRI) reporting system affect performance of MRI in men with a clinical suspicion of prostate cancer? BJU Int. 2020 01; 125(1):4-5. PMID: 31901008.
    Citations: 1     Fields:    Translation:Humans
  33. Knaapila J, Jambor I, Falagario U, Ettala O, Syvänen KT, Boström PJ. Reply to Joshua S. Jue and Mahmoud Alameddine's Letter to the Editor re: Juha Knaapila, Ivan Jambor, Ileana Montoya Perez, et al. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. Eur Urol Oncol 2020;3:648-656. Eur Urol Oncol. 2020 10; 3(5):711-712. PMID: 31882349.
    Citations: 2     Fields:    Translation:Humans
  34. Perez IM, Jambor I, Kauko T, Verho J, Ettala O, Falagario U, Merisaari H, Kiviniemi A, Taimen P, Syvänen KT, Knaapila J, Seppänen M, Rannikko A, Riikonen J, Kallajoki M, Mirtti T, Lamminen T, Saunavaara J, Pahikkala T, Boström PJ, Aronen HJ. Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI-IMPROD Trials). J Magn Reson Imaging. 2020 05; 51(5):1556-1567. PMID: 31750988.
    Citations: 12     Fields:    Translation:Humans
  35. Merisaari H, Taimen P, Shiradkar R, Ettala O, Pesola M, Saunavaara J, Boström PJ, Madabhushi A, Aronen HJ, Jambor I. Repeatability of radiomics and machine learning for DWI: Short-term repeatability study of 112 patients with prostate cancer. Magn Reson Med. 2020 06; 83(6):2293-2309. PMID: 31703155; PMCID: PMC7047644.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  36. Montoya Perez I, Jambor I, Pahikkala T, Airola A, Merisaari H, Saunavaara J, Alinezhad S, Väänänen RM, Tallgrén T, Verho J, Kiviniemi A, Ettala O, Knaapila J, Syvänen KT, Kallajoki M, Vainio P, Aronen HJ, Pettersson K, Boström PJ, Taimen P. Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machine-Learning Techniques. J Magn Reson Imaging. 2020 05; 51(5):1540-1553. PMID: 31588660.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  37. Jambor I, Falagario U, Ratnani P, Perez IM, Demir K, Merisaari H, Sobotka S, Haines GK, Martini A, Beksac AT, Lewis S, Pahikkala T, Wiklund P, Nair S, Tewari A. Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score. J Magn Reson Imaging. 2020 04; 51(4):1075-1085. PMID: 31566845.
    Citations: 10     Fields:    Translation:Humans
  38. Falagario UG, Martini A, Wajswol E, Treacy PJ, Ratnani P, Jambor I, Anastos H, Lewis S, Haines K, Cormio L, Carrieri G, Rastinehad AR, Wiklund P, Tewari A. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators. Eur Urol Oncol. 2020 10; 3(5):700-704. PMID: 31548130.
    Citations: 28     Fields:    Translation:Humans
  39. Knaapila J, Jambor I, Perez IM, Ettala O, Taimen P, Verho J, Kiviniemi A, Pahikkala T, Merisaari H, Lamminen T, Saunavaara J, Aronen HJ, Syvänen KT, Boström PJ. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. Eur Urol Oncol. 2020 10; 3(5):648-656. PMID: 31501082.
    Citations: 6     Fields:    Translation:Humans
  40. Toivonen J, Montoya Perez I, Movahedi P, Merisaari H, Pesola M, Taimen P, Boström PJ, Pohjankukka J, Kiviniemi A, Pahikkala T, Aronen HJ, Jambor I. Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization. PLoS One. 2019; 14(7):e0217702. PMID: 31283771; PMCID: PMC6613688.
    Citations: 34     Fields:    Translation:HumansCTClinical Trials
  41. Jambor I, Verho J, Ettala O, Knaapila J, Taimen P, Syvänen KT, Kiviniemi A, Kähkönen E, Perez IM, Seppänen M, Rannikko A, Oksanen O, Riikonen J, Vimpeli SM, Kauko T, Merisaari H, Kallajoki M, Mirtti T, Lamminen T, Saunavaara J, Aronen HJ, Boström PJ. Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. PLoS Med. 2019 06; 16(6):e1002813. PMID: 31158230; PMCID: PMC6546206.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  42. Saarinen I, Jambor I, Kim M, Kuisma A, Kemppainen J, Merisaari H, Eskola O, Koskenniemi AR, Perez IM, Boström P, Taimen P, Minn H. Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer. EJNMMI Res. 2019 May 31; 9(1):50. PMID: 31152256; PMCID: PMC6544711.
    Citations: 10     
  43. Merisaari H, Jambor I, Ettala O, Boström PJ, Montoya Perez I, Verho J, Kiviniemi A, Syvänen K, Kähkönen E, Eklund L, Pahikkala T, Vainio P, Saunavaara J, Aronen HJ, Taimen P. IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy. J Magn Reson Imaging. 2019 11; 50(5):1641-1650. PMID: 30903647.
    Citations: 5     Fields:    Translation:Humans
  44. Arvola S, Jambor I, Kuisma A, Kemppainen J, Kajander S, Seppänen M, Noponen T. Comparison of standardized uptake values between 99mTc-HDP SPECT/CT and 18F-NaF PET/CT in bone metastases of breast and prostate cancer. EJNMMI Res. 2019 Jan 24; 9(1):6. PMID: 30680469; PMCID: PMC6346696.
    Citations: 22     
  45. Montoya Perez I, Airola A, Boström PJ, Jambor I, Pahikkala T. Tournament leave-pair-out cross-validation for receiver operating characteristic analysis. Stat Methods Med Res. 2019 Oct-Nov; 28(10-11):2975-2991. PMID: 30126322; PMCID: PMC6745617.
    Citations: 3     Fields:    Translation:Humans
  46. Salminen A, Jambor I, Merisaari H, Ettala O, Virtanen J, Koskinen I, Veskimae E, Sairanen J, Taimen P, Kemppainen J, Minn H, Boström PJ. 11C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial). Cancer Imaging. 2018 Aug 02; 18(1):25. PMID: 30068379; PMCID: PMC6090957.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  47. Shiradkar R, Ghose S, Jambor I, Taimen P, Ettala O, Purysko AS, Madabhushi A. Radiomic features from pretreatment biparametric MRI predict prostate cancer biochemical recurrence: Preliminary findings. J Magn Reson Imaging. 2018 12; 48(6):1626-1636. PMID: 29734484; PMCID: PMC6222024.
    Citations: 53     Fields:    Translation:Humans
  48. Knaapila J, Kallio H, Hakanen AJ, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Gunell M, Boström PJ. Antibiotic susceptibility of intestinal Escherichia coli in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study. BJU Int. 2018 08; 122(2):203-210. PMID: 29533507.
    Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
  49. Algohary A, Viswanath S, Shiradkar R, Ghose S, Pahwa S, Moses D, Jambor I, Shnier R, Böhm M, Haynes AM, Brenner P, Delprado W, Thompson J, Pulbrock M, Purysko AS, Verma S, Ponsky L, Stricker P, Madabhushi A. Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: Preliminary findings. J Magn Reson Imaging. 2018 Feb 22. PMID: 29469937; PMCID: PMC6105554.
    Citations: 38     Fields:    
  50. Knaapila J, Gunell M, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Hakanen AJ, Boström PJ. Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort. Eur Urol Focus. 2019 05; 5(3):443-448. PMID: 29275146.
    Citations: 4     Fields:    Translation:Humans
  51. Jambor I. Optimization of prostate MRI acquisition and post-processing protocol: a pictorial review with access to acquisition protocols. Acta Radiol Open. 2017 Dec; 6(12):2058460117745574. PMID: 29242748; PMCID: PMC5724653.
    Citations: 6     
  52. Jambor I, Kuisma A, Kähkönen E, Kemppainen J, Merisaari H, Eskola O, Teuho J, Perez IM, Pesola M, Aronen HJ, Boström PJ, Taimen P, Minn H. Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial). Eur J Nucl Med Mol Imaging. 2018 03; 45(3):355-364. PMID: 29147764.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  53. Jambor I, Boström PJ, Taimen P, Syvänen K, Kähkönen E, Kallajoki M, Perez IM, Kauko T, Matomäki J, Ettala O, Merisaari H, Kiviniemi A, Dean PB, Aronen HJ. Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). J Magn Reson Imaging. 2017 10; 46(4):1089-1095. PMID: 28165653.
    Citations: 29     Fields:    Translation:Humans
  54. Ginsburg SB, Algohary A, Pahwa S, Gulani V, Ponsky L, Aronen HJ, Boström PJ, Böhm M, Haynes AM, Brenner P, Delprado W, Thompson J, Pulbrock M, Taimen P, Villani R, Stricker P, Rastinehad AR, Jambor I, Madabhushi A. Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study. J Magn Reson Imaging. 2017 07; 46(1):184-193. PMID: 27990722; PMCID: PMC5464994.
    Citations: 44     Fields:    Translation:HumansCTClinical Trials
  55. Ginsburg SB, Taimen P, Merisaari H, Vainio P, Boström PJ, Aronen HJ, Jambor I, Madabhushi A. Patient-specific pharmacokinetic parameter estimation on dynamic contrast-enhanced MRI of prostate: Preliminary evaluation of a novel AIF-free estimation method. J Magn Reson Imaging. 2016 12; 44(6):1405-1414. PMID: 27285161; PMCID: PMC5559229.
    Citations: 2     Fields:    Translation:Humans
  56. Salminen AP, Jambor I, Syvanen KT, Bostrom PJ. Update on novel imaging techniques for the detection of lymph node metastases in bladder cancer. Minerva Urol Nefrol. 2016 Apr; 68(2):138-49. PMID: 27271230.
    Citations: 6     Fields:    Translation:Humans
  57. Merisaari H, Movahedi P, Perez IM, Toivonen J, Pesola M, Taimen P, Boström PJ, Pahikkala T, Kiviniemi A, Aronen HJ, Jambor I. Fitting methods for intravoxel incoherent motion imaging of prostate cancer on region of interest level: Repeatability and gleason score prediction. Magn Reson Med. 2017 03; 77(3):1249-1264. PMID: 26924552.
    Citations: 25     Fields:    Translation:Humans
  58. Alinezhad S, Väänänen RM, Tallgrén T, Perez IM, Jambor I, Aronen H, Kähkönen E, Ettala O, Syvänen K, Nees M, Kallajoki M, Taimen P, Boström PJ, Pettersson K. Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue. Urol Oncol. 2016 06; 34(6):255.e15-22. PMID: 26857646.
    Citations: 2     Fields:    Translation:Humans
  59. Salminen AP, Jambor I, Syvänen KT, Boström PJ. Lymph node imaging in bladder cancer. Minerva Urol Nefrol. 2015 Dec 18. PMID: 26684180.
    Citations: 1     Fields:    
  60. Merisaari H, Toivonen J, Pesola M, Taimen P, Boström PJ, Pahikkala T, Aronen HJ, Jambor I. Diffusion-weighted imaging of prostate cancer: effect of b-value distribution on repeatability and cancer characterization. Magn Reson Imaging. 2015 Dec; 33(10):1212-1218. PMID: 26220861.
    Citations: 13     Fields:    Translation:Humans
  61. Jambor I, Pesola M, Merisaari H, Taimen P, Boström PJ, Liimatainen T, Aronen HJ. Relaxation along fictitious field, diffusion-weighted imaging, and T2 mapping of prostate cancer: Prediction of cancer aggressiveness. Magn Reson Med. 2016 May; 75(5):2130-40. PMID: 26094849.
    Citations: 8     Fields:    Translation:Humans
  62. Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, Kemppainen J, Kauppila E, Auren J, Merisaari H, Saunavaara J, Noponen T, Minn H, Aronen HJ, Seppänen M. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol. 2016; 55(1):59-67. PMID: 25833330.
    Citations: 56     Fields:    Translation:Humans
  63. Jambor I, Pesola M, Taimen P, Merisaari H, Boström PJ, Minn H, Liimatainen T, Aronen HJ. Rotating frame relaxation imaging of prostate cancer: Repeatability, cancer detection, and Gleason score prediction. Magn Reson Med. 2016 Jan; 75(1):337-44. PMID: 25733132.
    Citations: 9     Fields:    Translation:Humans
  64. Toivonen J, Merisaari H, Pesola M, Taimen P, Boström PJ, Pahikkala T, Aronen HJ, Jambor I. Mathematical models for diffusion-weighted imaging of prostate cancer using b values up to 2000 s/mm(2) : correlation with Gleason score and repeatability of region of interest analysis. Magn Reson Med. 2015 Oct; 74(4):1116-24. PMID: 25329932.
    Citations: 24     Fields:    Translation:Humans
  65. Jambor I, Merisaari H, Taimen P, Boström P, Minn H, Pesola M, Aronen HJ. Evaluation of different mathematical models for diffusion-weighted imaging of normal prostate and prostate cancer using high b-values: a repeatability study. Magn Reson Med. 2015 May; 73(5):1988-98. PMID: 25046482.
    Citations: 34     Fields:    Translation:Humans
  66. Merisaari H, Jambor I. Optimization of b-value distribution for four mathematical models of prostate cancer diffusion-weighted imaging using b values up to 2000 s/mm(2): simulation and repeatability study. Magn Reson Med. 2015 May; 73(5):1954-69. PMID: 25045885.
    Citations: 20     Fields:    Translation:Humans
  67. Jambor I, Kähkönen E, Taimen P, Merisaari H, Saunavaara J, Alanen K, Obsitnik B, Minn H, Lehotska V, Aronen HJ. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy. J Magn Reson Imaging. 2015 May; 41(5):1394-404. PMID: 24956412.
    Citations: 17     Fields:    Translation:Humans
  68. Jambor I, Merisaari H, Aronen HJ, Järvinen J, Saunavaara J, Kauko T, Borra R, Pesola M. Optimization of b-value distribution for biexponential diffusion-weighted MR imaging of normal prostate. J Magn Reson Imaging. 2014 May; 39(5):1213-22. PMID: 24127398.
    Citations: 19     Fields:    Translation:Humans
  69. Kähkönen E, Jambor I, Kemppainen J, Lehtiö K, Grönroos TJ, Kuisma A, Luoto P, Sipilä HJ, Tolvanen T, Alanen K, Silén J, Kallajoki M, Roivainen A, Schäfer N, Schibli R, Dragic M, Johayem A, Valencia R, Borkowski S, Minn H. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res. 2013 Oct 01; 19(19):5434-43. PMID: 23935037.
    Citations: 70     Fields:    Translation:Humans
  70. Roivainen A, Kähkönen E, Luoto P, Borkowski S, Hofmann B, Jambor I, Lehtiö K, Rantala T, Rottmann A, Sipilä H, Sparks R, Suilamo S, Tolvanen T, Valencia R, Minn H. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013 Jun; 54(6):867-72. PMID: 23564761.
    Citations: 36     Fields:    Translation:HumansCTClinical Trials
  71. Jambor I, Borra R, Kemppainen J, Lepomäki V, Parkkola R, Dean K, Alanen K, Arponen E, Nurmi M, Aronen HJ, Minn H. Improved detection of localized prostate cancer using co-registered MRI and 11C-acetate PET/CT. Eur J Radiol. 2012 Nov; 81(11):2966-72. PMID: 22342610.
    Citations: 17     Fields:    Translation:Humans
  72. Jambor I, Borra R, Kemppainen J, Lepomäki V, Parkkola R, Dean K, Alanen K, Arponen E, Nurmi M, Aronen HJ, Minn H. Functional imaging of localized prostate cancer aggressiveness using 11C-acetate PET/CT and 1H-MR spectroscopy. J Nucl Med. 2010 Nov; 51(11):1676-83. PMID: 20956477.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Jambor's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (148)
Co-Authors (1)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.